- Trial phase
- Approved (Phase 4 SYNCHRONICITY data reported July 2026)
- Time to market
- Already approved and marketed (FDA-approved September 2014 for DME; label expanded March 2025 for NIU-PS uveitis)
- Why 3/10
- ILUVIEN is already FDA-approved and commercialized with no pending PDUFA or pivotal readout in the next ~12 months. The recently announced positive Phase 4 SYNCHRONICITY data (July 13, 2026) is a commercial-support data readout, not a binary regulatory catalyst. As one product in ANI's diversified portfolio (~$75M of $883M total 2025 revenue), ILUVIEN alone cannot drive a major share-price move.
ILUVIEN is a steady commercial asset within ANI's larger Rare Disease transition story. The positive July 2026 Phase 4 SYNCHRONICITY data supports the uveitis label expansion's real-world use, but the stock's bigger drivers are Cortrophin Gel growth and overall margin expansion. Watch quarterly sales trends for ILUVIEN against the $78M-$83M 2026 guidance.
Price Chart
Executive Summary
ILUVIEN is a 36-month sustained-release corticosteroid intravitreal implant for diabetic macular edema (DME) and chronic non-infectious posterior uveitis (NIU-PS). Originally developed by Alimera Sciences and pSivida, it was acquired by ANI Pharmaceuticals in September 2024 for ~$381M. It generated $74.9M in net revenue for ANI in 2025 and is guided for $78M-$83M in 2026. ILUVIEN occupies a niche position behind anti-VEGF standard-of-care therapies (Eylea, Lucentis) for DME patients who have previously tolerated corticosteroids. In March 2025, the FDA approved a label expansion to include NIU-PS. Very recent Phase 4 SYNCHRONICITY data (July 13, 2026) showed positive six-month efficacy in uveitis, supporting commercial uptake. The drug faces competition from other corticosteroid implants (Ozurdex, YUTIQ) and market access headwinds with Medicare patients.
How It Works
ILUVIEN is a tiny, sustained-release corticosteroid implant injected into the vitreous gel of the eye. It delivers a steady, low dose of fluocinolone acetonide (a steroid) for up to 36 months to reduce inflammation and swelling in the retina, treating diabetic macular edema and chronic uveitis. A single injection replaces the need for frequent eye injections.
Trial Status
ILUVIEN is FDA-approved for two indications. The Phase 4 SYNCHRONICITY trial (single-arm, open-label) met both co-primary endpoints at 6 months, BCVA improved 3.6 ETDRS letters (p≤0.0077) and CST fell 157.5 microns (p<0.0001), with full results to be presented at a future medical meeting. The NEW DAY Phase 4 trial in DME was published in Ophthalmology journal in April 2026.
The Two-Sided Case
Upcoming Catalysts
- Commercial sales trajectory: Q2 2026 ILUVIEN net revenue (estimated early August 2026) vs. $78M-$83M full-year guidance.
- Full SYNCHRONICITY Phase 4 results presented at an upcoming medical meeting (date TBD).
- Potential further payer coverage expansion for the NIU-PS indication as Medicare and commercial policies continue to update.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ANI Pharmaceuticals, Inc. Press Release ANIP ·Originating report